178 related articles for article (PubMed ID: 24155641)
1. Chemotherapy (gemcitabine, docetaxel plus gemcitabine, doxorubicin, or trabectedin) in inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a clinical practice guideline.
Gupta AA; Yao X; Verma S; Mackay H; Hopkins L
Curr Oncol; 2013 Oct; 20(5):e448-54. PubMed ID: 24155641
[TBL] [Abstract][Full Text] [Related]
2. Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a systematic review.
Gupta AA; Yao X; Verma S; Mackay H; Hopkins L;
Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):346-55. PubMed ID: 23295078
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
[TBL] [Abstract][Full Text] [Related]
4. A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma.
Gadducci A; Grosso F; Scambia G; Raspagliesi F; Colombo N; Grignani G; Casali P; Sanfilippo R; Buonadonna A; Santoro A; Bruzzone M; Artioli G; Lorusso D; Biagioli E; Fossati R; Galli F; Negri E; Rulli E; Torri V; D'Incalci M
Br J Cancer; 2018 Aug; 119(5):565-571. PubMed ID: 30057406
[TBL] [Abstract][Full Text] [Related]
5. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
6. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).
Pautier P; Floquet A; Penel N; Piperno-Neumann S; Isambert N; Rey A; Bompas E; Cioffi A; Delcambre C; Cupissol D; Collin F; Blay JY; Jimenez M; Duffaud F
Oncologist; 2012; 17(9):1213-20. PubMed ID: 22907974
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Pautier P; Italiano A; Piperno-Neumann S; Chevreau C; Penel N; Firmin N; Boudou-Rouquette P; Bertucci F; Balleyguier C; Lebrun-Ly V; Ray-Coquard I; Kalbacher E; Bardet A; Bompas E; Collard O; Isambert N; Guillemet C; Rios M; Archambaud B; Duffaud F;
Lancet Oncol; 2022 Aug; 23(8):1044-1054. PubMed ID: 35835135
[TBL] [Abstract][Full Text] [Related]
8. Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan.
Takano T; Niikura H; Ito K; Nagase S; Utsunomiya H; Otsuki T; Toyoshima M; Tokunaga H; Kaiho-Sakuma M; Shiga N; Nagai T; Tanaka S; Otsuki A; Kurosawa H; Shigeta S; Tsuji K; Yamaguchi T; Yaegashi N
Int J Clin Oncol; 2014 Oct; 19(5):897-905. PubMed ID: 24149774
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide-based combination chemotherapy in advanced soft-tissue sarcoma: a practice guideline.
Verma S; Younus J; Stys-Norman D; Haynes AE; Blackstein M
Curr Oncol; 2007 Aug; 14(4):144-8. PubMed ID: 17710206
[TBL] [Abstract][Full Text] [Related]
10. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Hensley ML; Blessing JA; Degeest K; Abulafia O; Rose PG; Homesley HD
Gynecol Oncol; 2008 Jun; 109(3):323-8. PubMed ID: 18394689
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
Hensley ML; Maki R; Venkatraman E; Geller G; Lovegren M; Aghajanian C; Sabbatini P; Tong W; Barakat R; Spriggs DR
J Clin Oncol; 2002 Jun; 20(12):2824-31. PubMed ID: 12065559
[TBL] [Abstract][Full Text] [Related]
12. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
13. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological treatment for uterine leiomyosarcomas.
Gadducci A; Guerrieri ME
Expert Opin Pharmacother; 2015 Feb; 16(3):335-46. PubMed ID: 25418060
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and toxicities of doxorubicin plus ifosfamide in the second-line treatment of uterine leiomyosarcoma.
Niu SY; Sun L; Hsu ST; Hwang SF; Liu CK; Shih YH; Lu TF; Chen YF; Lai LC; Chang PL; Lu CH
Front Oncol; 2023; 13():1282596. PubMed ID: 38090488
[TBL] [Abstract][Full Text] [Related]
17. Management of single brain metastasis: a practice guideline.
Mintz A; Perry J; Spithoff K; Chambers A; Laperriere N
Curr Oncol; 2007 Aug; 14(4):131-43. PubMed ID: 17710205
[TBL] [Abstract][Full Text] [Related]
18. Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.
Ricci S; Stone RL; Fader AN
Gynecol Oncol; 2017 Apr; 145(1):208-216. PubMed ID: 28209496
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
20. A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery.
Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Saada-Bouzid E; Bertucci F; Bompas E; Alexandre J; Collard O; Lebrun-Ly V; Soulier P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
ESMO Open; 2021 Aug; 6(4):100209. PubMed ID: 34325109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]